MedTrace Logo

Prescription of Letrozole for Uterine Myoma

NCT06143631 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-05-20

No results posted yet for this study

Summary

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

Conditions

  • Leiomyoma, Uterine
  • Leiomyoma
  • Fibroid
  • Fibroid Uterus

Interventions

DRUG

Letrozole 2.5mg

Oral letrozole 2.5mg/day

OTHER

Placebo

Placebo capsule

Sponsors & Collaborators

Principal Investigators

  • Vanessa Jacoby, MD, MAS · University of California, San Francisco

  • Alison Huang, MD, MAS · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
53 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-24
Primary Completion
2027-09-06
Completion
2027-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06143631 on ClinicalTrials.gov